Biomimetic cellular vectors for enhancing drug delivery to the lungs.

Sci Rep 2020 01 13;10(1):172. Epub 2020 Jan 13.

Center for Biomimetic Medicine, Houston Methodist Research Institute, Houston, TX, USA.

Despite recent advances in drug delivery, the targeted treatment of unhealthy cells or tissues continues to remain a priority. In cancer (much like other pathologies), delivery vectors are designed to exploit physical and biological features of unhealthy tissues that are not always homogenous across the disease. In some cases, shifting the target from unhealthy tissues to the whole organ can represent an advantage. Specifically, the natural organ-specific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, and spleen can be strategically exploited to enhance drug delivery. Herein, we outline the development of a cell-based delivery system using macrophages as a delivery vehicle. When loaded with a chemotherapeutic payload (i.e., doxorubicin), these cellular vectors (CELVEC) were shown to provide continued release within the lung. This study provides proof-of-concept evidence of an alternative class of biomimetic delivery vectors that capitalize on cell size to provide therapeutic advantages for pulmonary treatments.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-55909-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957529PMC
January 2020
5.078 Impact Factor

Publication Analysis

Top Keywords

drug delivery
12
cellular vectors
8
unhealthy tissues
8
delivery vectors
8
delivery
7
advantage natural
4
organ represent
4
represent advantage
4
lung study
4
natural organ-specific
4
retention nanotherapeutics
4
continued release
4
organ-specific retention
4
release lung
4
study proof-of-concept
4
target unhealthy
4
evidence alternative
4
loaded chemotherapeutic
4
tissues homogenous
4
alternative class
4

Altmetric Statistics

Similar Publications